LoRusso, Patricia

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet

COVID-19 and healthcare impactsCOVID-19 Clinical Research Studies

Cited by 1,726

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 645

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Flaherty, K. T., LoRusso, P. M., DeMichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O'Dwyer, P. J., & Schwartz, G. K. (2012) · Clinical Cancer Research

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 366

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

Sacher, A., LoRusso, P., Patel, M. R., Miller, W. H., Garralda, E., Forster, M. D., Santoro, A., Falcon, A., Kim, T. W., Paz-Ares, L., et al. (2023) · New England Journal of Medicine

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 328

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

Schwartz, G. K., LoRusso, P. M., Dickson, M. A., Randolph, S. S., Shaik, M. N., Wilner, K. D., Courtney, R., & O'Dwyer, P. J. (2011) · British Journal of Cancer

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 260

The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development

Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery

Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins

Cited by 254

Discovery of a Potent Small-Molecule Antagonist of Inhibitor of Apoptosis (IAP) Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

Flygare, J. A., Beresini, M., Budha, N., Chan, H., Chan, I. T., Cheeti, S., Cohen, F., Deshayes, K., Doerner, K., Eckhardt, S. G., et al. (2012) · Journal of Medicinal Chemistry

Cell death mechanisms and regulationHeterocyclic Compound Synthesis and Bioactivity

Cited by 252

A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014

Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., et al. (2015) · Clinical Cancer Research

Alzheimer's disease research and treatmentsWnt/β-catenin signaling in development and cancer

Cited by 218

Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors

Naing, A., LoRusso, P., Fu, S., Hong, D. S., Anderson, P., Benjamin, R. S., Ludwig, J., Chen, H. X., Doyle, L. A., & Kurzrock, R. (2012) · Clinical Cancer Research

Sarcoma Diagnosis and TreatmentPI3K/AKT/mTOR signaling in cancer

Cited by 205

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Desai, J., Alonso, G., Kim, S. H., Cervantes, A., Karasic, T., Medina, L., Shacham-Shmueli, E., Cosman, R., Falcon, A., Gort, E., et al. (2024) · Nature Medicine

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors

Ferrarotto, R., Eckhardt, G., Patnaik, A., LoRusso, P., Faoro, L., Heymach, J. V., Kapoun, A. M., Xu, L., & Munster, P. (2018) · Annals of Oncology

Cancer Immunotherapy and BiomarkersMonoclonal and Polyclonal Antibodies Research

Cited by 138

The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study

LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., et al. (2023) · Cancer Discovery

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 101

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Shapiro, G. I., LoRusso, P., Kwak, E., Pandya, S., Rudin, C. M., Kurkjian, C., Cleary, J. M., Pilat, M. J., Jones, S., de Crespigny, A., et al. (2020) · Investigational New Drugs

PI3K/AKT/mTOR signaling in cancerMelanoma and MAPK Pathways

Cited by 90

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., et al. (2018) · British Journal of Cancer

Proteoglycans and glycosaminoglycans researchHydrogels: synthesis, properties, applications

Cited by 83

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Patel, M. R., Bauer, T. M., Jimeno, A., Wang, D., LoRusso, P., Do, K. T., Stemmer, S. M., Maurice-Dror, C., Geva, R., Zacharek, S., et al. (2020) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 69

608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC)

Park, W., Kasi, A., Spira, A. I., Berlin, J. D., Wang, J. S., Herzberg, B., Kuboki, Y., Kitano, S., Pelster, M., Goldman, J. W., et al. (2024) · Annals of Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 46

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations.

Tolcher, A. W., Park, W., Wang, J. S., Spira, A. I., Janne, P. A., Lee, H.-J., Gill, S., LoRusso, P., Herzberg, B., Goldman, J. W., et al. (2023) · Journal of Clinical Oncology

Protein Degradation and InhibitorsPancreatic and Hepatic Oncology Research

Cited by 33

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Choi, Y., Dharia, N. V., Jun, T., Chang, J., Royer-Joo, S., Yau, K. K., Assaf, Z. J., Aimi, J., Sivakumar, S., Montesion, M., et al. (2024) · Clinical Cancer Research

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 23

One Step at a Time — Clinical Evidence That KRAS Is Indeed Druggable

LoRusso, P. M., & Sebolt-Leopold, J. S. (2020) · New England Journal of Medicine

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 21

Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Gounder, M. M., Bauer, T. M., Schwartz, G. K., LoRusso, P., Kumar, P., Kato, K., Tao, B., Hong, Y., Patel, P., & Hong, D. (2020) · European Journal of Cancer

Sarcoma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 19

Phase I study of REGN421 (R)/SAR153192, a fully‐human delta‐like ligand 4 (Dll4) monoclonal antibody (mAb), in patients with advanced solid tumors

Jimeno, A., LoRusso, P., Strother, R. M., Diamond, J. R., Plato, L., Younger, A., Messersmith, W. A., Kittaneh, M., Sawyer, D., Adriaens, L., et al. (2013) · Journal of Clinical Oncology

Angiogenesis and VEGF in CancerCancer Immunotherapy and Biomarkers

Cited by 15

LBA27 First-in-human results of STX-478, a mutant-selective PI3Ka inhibitor, in advanced solid tumor patients

Montero, A. J., Giordano, A., Jhaveri, K., Munster, P., Rodon, J., Lorusso, P., Orr, D., Bartolomé Arcilla, J., Italiano, A., Elias, A., et al. (2024) · Annals of Oncology

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 9